구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd)) Merck Sharp & Dohme LLC·Small-Cell Lung Cancer 41 trials |
|---|---|
Overview Program | Ifinatamab Deruxtecan (I-DXd) |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Small-Cell Lung Cancer |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | Deruxtecan in Patients With Extensive-Stage Small |
MoA Mechanism | targeting cervical cancer, effectively eliminates tumor cells through specific antigen recognition while concurrently depleting pro-tumor VEGFA + TANs via Fcγ receptor |
MoA Biomarker | B7-H3) is minimally expressed in normal tissues but high |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | PD |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | interstitial lung disease (ILD) as determined by the ILD adjudication committee was reported in 1 |
Clinical Safety signal | interstitial lung disease (ILD) as determined by the ILD adjudication committee was reported in 1 |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd)) Merck Sharp & Dohme LLC·Small-Cell Lung Cancer 41 trials |
|---|---|
Overview Program | Ifinatamab Deruxtecan (I-DXd) |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Small-Cell Lung Cancer |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | Deruxtecan in Patients With Extensive-Stage Small |
MoA Mechanism | targeting cervical cancer, effectively eliminates tumor cells through specific antigen recognition while concurrently depleting pro-tumor VEGFA + TANs via Fcγ receptor |
MoA Biomarker | B7-H3) is minimally expressed in normal tissues but high |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | PD |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | interstitial lung disease (ILD) as determined by the ILD adjudication committee was reported in 1 |
Clinical Safety signal | interstitial lung disease (ILD) as determined by the ILD adjudication committee was reported in 1 |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교